Rufinamide: Pharmacology, clinical trials, and role in clinical practice

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1497-1501

  Cheng Hakimian, A ^a   Anderson, G D ^a   Miller, J W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anti epileptic drugs; Epilepsy; Lennox Gastautsyndrome; Localisation related epilepsy; Rufinamide; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CPG 33101; CYTOCHROME P450; FELBAMATE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; SODIUM ION; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ACTION POTENTIAL; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; INHIBITION KINETICS; LENNOX GASTAUT SYNDROME; META ANALYSIS; NERVE CELL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; SEIZURE; SOMNOLENCE; SYSTEMATIC REVIEW; TREMOR; VOMITING;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; EPILEPSY; HUMANS; TRIAZOLES;

EID: 33749818806     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01173.x     Document Type: Article

References (22)

1. Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a first unprovoked seizure; an extended follow-up. Neurology 1990; 400: 1163-70.
2. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 31-9.
3. Spencer SS, Berg AT, Vickrey BG et.al. Predicting long-term seizure outcome after resective epilepsy surgery; the multicenter study. Neurology 2005; 65: 912-8.
4. Kelley K, Theodore W. Prognosis 30years after temporal lobectomy. Neurology 2005; 64: 1974-6.
5. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999; 34: 1-41.
6. Cardot JM, Lecaillon JB, Czendlik C, Godbillon J. The influence of food on the disposition of the antiepileptic drug rufinamide in healthy volunteers. Biopharm Drug Dispos 1998; 19: 259-62.
7. Cheung WK, Kianifard F, Wong A et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200mg tablets and 400mg suspension. Pharm Res 1995; 12: 1878-82.
8. Waldmeier F. Metabolism of the new anticonvulsant trial drug rufinamide (CGP33101) in healthy male volunteers. Epilepsia 1996; 37 (Suppl. 5): 167.
9. Chang S-W, Choi L, Karolchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 1998; 39 (Suppl. 6): 59.
10. Sachdeo RC, Rosenfeld WE, Choi L, Yeh C-M, Cooper AN, Karolchyk MA. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia 1998; 39 (Suppl. 6): 166-7.
11. Palhagen S, Canger R, Henriksen O, van Parys JA, Riviere ME, Karolchyk MA. Rufinamide: A double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001; 43: 115-24.
12. Vasquez B. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy resistant partial onset seizures. Epilepsia 2000; 41 (Suppl. 7): 255.
13. Glauser T, Kluger G, Sachedo R et.al. Efficacy and Safety of Rufinamide Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome (LGS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Trial. Miami Beach, FL: Late Breaking News at the American Academy of Neurology, 57th Annual Meeting, April 6-9, 2005.
14. Krauss G, Perdomo C, Arroyo S. Short and Long Term Safety of Rufinamide in Patients with Epilepsy. San Diego, CA, USA: Poster presentation at the 59th Annual Meeting of the American Epilepsy Society, December 2-6, 2006.
15. Litzinger M. Safety and Efficacy of open label rufinamide as adjunctive therapy in pediatric patients with partial seizures. Epilepsia 1999; 40 (Suppl. 7): 114.
16. Marchand M, Critchley D, Nagy C et al. The Effect of Rufinamide on the QT Interval in Healthy Subjects Treated During 18days with Multiple Ascending Doses: A Population PKPD Analysis. Abstract 785 of the Annual Meeting of the Population Approach Group in Europe, 2005.
17. Aldenkamp A, Alpherts W. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006; 47: 1153-9.
18. Willmore J. Clinical pharmacology of new antiepileptic drugs. Neurology 2000; 55 (11 Suppl. 3): 17-34.
19. Svendsen KD, Choid L, Chen B-L. Single-center, open-label, multiple dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia 1998; 39 (Suppl. 6): 59.
20. Motte J, Trevathan E, Arvidsson JF et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut Syndrome. N Engl J Med 1997; 337: 1807-12.
21. Sachdeo R, Glauser T, Ritter F et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut Syndrome: Topiramate YL Study Group. Neurology 1999; 52: 1882-7.
22. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 1993; 1328: 29-33.